IOL Chemicals and Pharma gets European regulator nod for Paracetamol exports

The company started commercial production of the same in 2022 in its Punjab-based facility where it is also backward integrated to produce the key starting material for Paracetamol. At present, IOL has a total capacity of 3,600 tonnes to produce Paracetamol.

Medical Dialogues team had earlier reported that the company had received EDQM certification to supply Pantoprazole Sodium Sesquihydrate API across European market. Pantoprazole Sodium Sesquihydrate are proton pump inhibitors used in drugs to suppress gastric acid secretion.

Read also: IOL Chemicals and Pharma gets EDQM certification to supply Pantoprazole Sodium Sesquihydrate API in Europe

IOL Chemicals and Pharmaceuticals Limited (IOLCP) Company was established in 1986. IOLCP has wide presence across major therapeutic categories like, Pain Management, anti-convulsants, antidiabetes, anti-cholesterol and anti-platelets. The Company’s product portfolio includes APIs; Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine, Pantoprazole, Paracetamol and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene, Mono Chloro Acetic Acid and Acetyl Chloride. The Company has DSIR approved R&D which is fully equipped to validate existing processes. The Central and State Government approved Effluent Treatment Plant (ETP) had been set up with Zero Liquid Discharge (ZLD) system along with 17 MW captive Co-Generation plant for self -reliance. The Company is ISO 9001:2015, 14001:2015 and BS OHSAS 18001:2007 certified.

Read also: Vikas Vij appointed as new CEO of IOL Chemicals and Pharma